Lexaria Bioscience expands studies of proprietary platform

Lexaria Bioscience announces the availability of a broadcast titled, “Can Diabetes, Weight-Loss Drugs Get Even Better?” The company said, “It shouldn’t be surprising that analysts at Markets and Research estimate the global diabetes drug market at $63.1 billion in 2021 on its way to $82.93 billion in 2027, while the global market for diabetes devices was valued at another $26.1 billion and growing 7.5% annually. Due to the pain and unpleasantness of injections, many diabetes sufferers prefer to treat their condition with drugs rather than devices, if they have the choice. Some of the most popular type 2 diabetes in recent years are GLP-1 receptor agonists. They work by mimicking the effects of the naturally occurring hormone GLP-1, which helps to regulate blood sugar levels and appetite.”